Skip to content


You currently have no items in your basket.

Total (excl. vat) £0.000
View basket & checkout
Proteins and Peptides

Amyloid Beta Peptide 1-42 (HFIP treated) Monomers

Product Sizes
100 ug
500 ug
1 mg
About this Product
Additional Names:
Abeta Protein, Abeta peptide, Amyloid beta peptide, Beta amyloid peptide, amyloid beta precursor protein peptide, APP
Cell-based/Functional Assay, Western Blot
Extra Details:
Our amyloid beta peptide 1-42 (AB Beta42) is produced synthetically and treated with 1,1,1,3,3,3-Hexafluoro-2-propanol (HFIP) prior to drying which breaks down pre-formed fibrils and monomerizes the peptide, as previously published (1,2). Upon resuspension in DMSO/dH2O, our AB Beta42 presents as a monomeric peptide without fibrils when observed under TEM, AFM and on a Western Blot with an anti-amyloid beta antibody. In contrast to AB42 oligomer and fibril constructs, our AB Beta42 monomers were not toxic to primary rat cortical neurons. In the brain, amyloid beta peptide (AB Beta) is generated by protease cleavage of amyloid precursor protein (APP), which aggregates into oligomers, protofibrils, fibrils and ultimately plaques in neurodegenerative diseases. The accumulation of AB Beta plaques in the brain is considered a hallmark of Alzheimer's disease (AD), and most of the drugs tested for AD in the past 20 years have targeted amyloid beta accumulation (3). Soluble AB Beta oligomers isolated from the brains of AD patients or those generated in vitro potently impaired synapse structure and function (4). AB Beta oligomers generated in vitro were toxic to PC12 cells (2) and SH-SY5Y cells (5). AB Beta was demonstrated to interact with tauopathies to affect neurodegeneration in AD patients (6) and accumulations of AB Beta were shown to be associated with lower survival rates in Parkinson's disease patients with dementia (7).
Molecular Weight:
4.5 kDa
Shipping Conditions:
Blue Ice
Storage Conditions:
StressMarq Biosciences
Proteins, Peptides, Small Molecules & Other Biomolecules: Synthetic